COMMUNIQUÉS West-GlobeNewswire

Annual General Meeting of Kuros Biosciences approves all resolutions
15/04/2026
Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, [...]
Inteleos Foundation Announces 2026 MedMissions Award to Advance Maternal Health Ultrasound Access in Five Nations
15/04/2026
ROCKVILLE, Md., April 15, 2026 (GLOBE NEWSWIRE) -- The Inteleos Foundation today announced five recipients of its 2026 MedMissions Award, supporting maternal health ultrasound access in Malawi, Sierra Leone, Kenya, [...]
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
15/04/2026
COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
15/04/2026
- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango [...]
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
15/04/2026
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first [...]
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
15/04/2026
Call scheduled for today, Wednesday, April 15, 2026, at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS) , a leading medical device and [...]
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
15/04/2026
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend previously published [...]
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
15/04/2026
Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. ( [...]
Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026
15/04/2026
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, using proprietary linker and ADC platform technologies CLIO-8221 is a [...]
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
15/04/2026
TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years TONMYA commercially launched in the U.S. in [...]
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases
15/04/2026
– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential best-in-disease oral therapy for [...]
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
15/04/2026
Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
15/04/2026
Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as first President [...]
Cannabis Industry Pioneers Launch grnroom, a Creative Marketing Agency
15/04/2026
VANCOUVER, British Columbia and TORONTO, April 15, 2026 (GLOBE NEWSWIRE) -- After more than a decade building brands, media platforms, and cultural moments within the cannabis industry, a group of experienced operators [...]
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
15/04/2026
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG [...]
neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
15/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy ® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal [...]
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
15/04/2026
Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women’s Health PHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE [...]
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
15/04/2026
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects [...]
Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome
15/04/2026
First Olmsted syndrome patient dosed in global Phase 1b study Company now operating under its new name, Orvida Pharma NESS ZIONA, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma (formerly Kamari Pharma), a [...]

Pages